tirzepatide wisconsin Weight Loss Injections GLP-1 Weight Loss Program |

Other Reported Vision Issues From Wegovy In addition to NAION, people with diabetes or cardiovascular risk factors who take Wegovy may still be at risk for other common eye conditions such as diabetic retinopathy, macular edema, or ocular migraines (although these conditions can occur in people not taking Wegovy)

FDA Adverse Event Reporting System (FAERS) data through 2024 confirms nausea as the single most frequently reported adverse event for semaglutide products, appearing in over 30% of all submitted reports (FDA FAERS Public Dashboard)

ABOM, is a board-certified family medicine and obesity medicine physician currently at Norman Regionals Primary Care South OKC clinic

While metabolic outcomes are robust, dedicated cardiovascular outcomes trials for tirzepatide are still ongoing

The risk of vomiting increases substantially

The primary driver in most fat burners is caffeine